USD
+$0.00
(+0.00%
)At Close (As of Oct 31, 2025)
$108.79M
Market Cap
-
P/E Ratio
-0.04
EPS
$4.20
52 Week High
$1.41
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) | 
|---|---|
| Gross Profit | -$26K | 
| Total Revenue | $0 | 
| Cost Of Revenue | $26K | 
| Costof Goods And Services Sold | $26K | 
| Operating Income | -$29M | 
| Selling General And Administrative | $11M | 
| Research And Development | $17M | 
| Operating Expenses | $29M | 
| Investment Income Net | - | 
| Net Interest Income | $1.1M | 
| Interest Income | $1.1M | 
| Interest Expense | - | 
| Non Interest Income | - | 
| Other Non Operating Income | - | 
| Depreciation | - | 
| Depreciation And Amortization | $26K | 
| Income Before Tax | -$28M | 
| Income Tax Expense | - | 
| Interest And Debt Expense | - | 
| Net Income From Continuing Operations | -$28M | 
| Comprehensive Income Net Of Tax | - | 
| Ebit | -$28M | 
| Ebitda | -$27M | 
| Net Income | -$28M | 
| Field | Value (USD) | 
|---|---|
| Total Assets | $99M | 
| Total Current Assets | $98M | 
| Cash And Cash Equivalents At Carrying Value | $56M | 
| Cash And Short Term Investments | $56M | 
| Inventory | - | 
| Current Net Receivables | - | 
| Total Non Current Assets | $149K | 
| Property Plant Equipment | - | 
| Accumulated Depreciation Amortization Ppe | - | 
| Intangible Assets | - | 
| Intangible Assets Excluding Goodwill | - | 
| Goodwill | - | 
| Investments | - | 
| Long Term Investments | - | 
| Short Term Investments | $41M | 
| Other Current Assets | $908K | 
| Other Non Current Assets | - | 
| Total Liabilities | $3.7M | 
| Total Current Liabilities | $3.7M | 
| Current Accounts Payable | $943K | 
| Deferred Revenue | - | 
| Current Debt | - | 
| Short Term Debt | $221K | 
| Total Non Current Liabilities | $0 | 
| Capital Lease Obligations | $111K | 
| Long Term Debt | - | 
| Current Long Term Debt | - | 
| Long Term Debt Noncurrent | - | 
| Short Long Term Debt Total | $111K | 
| Other Current Liabilities | $2.6M | 
| Other Non Current Liabilities | - | 
| Total Shareholder Equity | $95M | 
| Treasury Stock | - | 
| Retained Earnings | -$94M | 
| Common Stock | $69K | 
| Common Stock Shares Outstanding | $24M | 
| Field | Value (USD) | 
|---|---|
| Operating Cashflow | -$19M | 
| Payments For Operating Activities | - | 
| Proceeds From Operating Activities | - | 
| Change In Operating Liabilities | - | 
| Change In Operating Assets | - | 
| Depreciation Depletion And Amortization | $26K | 
| Capital Expenditures | $0 | 
| Change In Receivables | - | 
| Change In Inventory | - | 
| Profit Loss | - | 
| Cashflow From Investment | -$37M | 
| Cashflow From Financing | $103M | 
| Proceeds From Repayments Of Short Term Debt | - | 
| Payments For Repurchase Of Common Stock | - | 
| Payments For Repurchase Of Equity | - | 
| Payments For Repurchase Of Preferred Stock | - | 
| Dividend Payout | - | 
| Dividend Payout Common Stock | - | 
| Dividend Payout Preferred Stock | - | 
| Proceeds From Issuance Of Common Stock | - | 
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - | 
| Proceeds From Issuance Of Preferred Stock | - | 
| Proceeds From Repurchase Of Equity | - | 
| Proceeds From Sale Of Treasury Stock | - | 
| Change In Cash And Cash Equivalents | - | 
| Change In Exchange Rate | - | 
| Net Income | -$28M | 
| Field | Value (USD) | 
|---|---|
| Gross Profit | -$26K | 
| Total Revenue | $0 | 
| Cost Of Revenue | $26K | 
| Costof Goods And Services Sold | $26K | 
| Operating Income | -$29M | 
| Selling General And Administrative | $11M | 
| Research And Development | $17M | 
| Operating Expenses | $29M | 
| Investment Income Net | - | 
| Net Interest Income | $1.1M | 
| Interest Income | $1.1M | 
| Interest Expense | - | 
| Non Interest Income | - | 
| Other Non Operating Income | - | 
| Depreciation | - | 
| Depreciation And Amortization | $26K | 
| Income Before Tax | -$28M | 
| Income Tax Expense | - | 
| Interest And Debt Expense | - | 
| Net Income From Continuing Operations | -$28M | 
| Comprehensive Income Net Of Tax | - | 
| Ebit | -$28M | 
| Ebitda | -$27M | 
| Net Income | -$28M | 
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Atlanta, Georgia, dedicated to advancing innovative therapies for Parkinson's disease (PD) and related neurodegenerative disorders. The company employs a novel dual-targeting approach that addresses both central and peripheral mechanisms of neurodegeneration, aiming to tackle significant unmet medical needs within the PD patient population. With a robust pipeline of therapeutics currently in clinical development, Inhibikase is well-positioned to drive meaningful advancements in PD treatment, ultimately striving to improve the quality of life for patients coping with these challenging conditions.